Pharm Tech Titans

Lancet 352, 1347-1351. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH (2002) The avoidance of dementia with antihypertensive procedure: New proof from the Systolic Hypertension in Europe (Syst-Eur) examine. Acta Neurol Scand 97, 386-392. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, Babeanu S, Bossini A, GilExtremera B, Girerd X, Laks T, Lilov E, Moisseyev V, TuomilehtoJ, Vanhanen H, Webster J, Yodfat Y, Fagard R (1998) Prevention of dementia in randomised doubleblind placebo-managed Systolic Hypertension in Europe (Syst-Eur) demo. Brain Res 853, 81-92. Zaczek R, Chorvat RJ, Saye JA, Pierdomenico ME, Maciag CM, Logue AR, Fisher BN, Rominger DH, Earl RA (1998) Two new strong neurotransmitter launch enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)9(10H)-anthracenone: Comparison to linopirdine. Br J Clin Pharmacol 28, 1-16. van Dyck CH, Lin CH, Robinson R, Cellar J, Smith EO, Nelson JC, Arnsten AF, Hoffer PB (1997) The acetylcholine releaser linopirdine will increase parietal regional cerebral blood flow in Alzheimer’s ailment. Psychopharmacology (Berl) 132, 217-226. Borjesson A, Karlsson T, Adolfsson R, Ronnlund M, Nilsson L (1999) Linopirdine (DUP 996): Cholinergic treatment of older grownups employing successive and nonsuccessive tests.

Biochim Biophys Acta 1812, 15841590. Copenhaver PF, Anekonda TS, Musashe D, Robinson KM, Ramaker JM, Swanson TL, Wadsworth TL, Kretzschmar D, Woltjer RL, Quinn JF (2011) A translational continuum of product methods for assessing remedy methods in Alzheimer’s condition: Isradipine as a candidate drug. Brain Res 762, 203-210. Bourinet E, Stotz SC, Spaetgens RL, Dayanithi G, Lemos J, Nargeot J, Zamponi GW (2001) Interaction of SNX482 with domains III and IV inhibits activation gating of alpha(1E) (Ca(V)2.3) calcium channels. Alzheimer’s sickness. Biofactors 37, 189-196. Yagami T, Kohma H, Yamamoto Y (2012) L-form voltagedependent calcium channels as therapeutic targets for neurodegenerative conditions. fifty nine Anekonda TS, Quinn JF, Harris C, Frahler K, Wadsworth TL, Woltjer RL (2011) L-sort voltage-gated calcium channel blockade with isradipine as a therapeutic technique for Alzheimer’s ailment. Neurobiol Dis 41, 62-70. Anekonda TS, Quinn JF (2011) Calcium channel blocking as a therapeutic method for Alzheimer’s illness: The situation for isradipine. CNS Neurol Disord Drug Targets 10, 635-647. Cuello AC (2012) Gangliosides, NGF, brain growing older and condition: A mini-evaluation with own reflections.

J Mol Neurosci 40, 230-235. Cuello AC, Ferretti MT, Iulita MF (2012) Preplaque (’preclinical’) Abeta-induced swelling and nerve expansion factor deregulation in transgenic types of Alzheimer’s ailment-like amyloid pathology. Mol Pharmacol 60, 753760. Schindowski K, Belarbi K, Buee L (2008) Neurotrophic factors in Alzheimer’s illness: Role of axonal transportation. Eur J Pharmacol 659, 124-129. W. Froestl et al. Eur J Pharmacol 332, 121-131. Paroczai M, Kiss B, Karpati E (1998) Effect of RGH-2716 on learning and memory deficits of youthful and aged rats in h2o-labyrinth. J Pharmacol Sci 93, 188-196. Iwasaki K, Egashira N, Takagaki Y, Yoshimitsu Y, HatipAl-Khatib I, Mishima K, Fujiwara M (2007) Nilvadipine stops the impairment of spatial memory induced by cerebral ischemia put together with beta-amyloid in rats. Mol Med 17, 149-162. Iwasaki K, Mishima K, Egashira N, Al-Khatib IH, Ishibashi D, Irie K, Kobayashi H, Egawa T, Fujiwara M (2003) Effect of nilvadipine on the cerebral ischemiainduced impairment of spatial memory and hippocampal apoptosis in rats.

Cell Mol Neurobiol 26, 619-633. Capsoni S, Tiveron C, Amato G, Vignone D, pornstars-below-the-age-of Cattaneo A (2010) Peripheral neutralization of nerve expansion issue induces immunosympathectomy and central neurodegeneration in transgenic mice. Capsoni S, Cattaneo A (2006) On the molecular foundation linking nerve progress factor (NGF) to Alzheimer’s illness. Brain Res Bull 45, 475-488. Fukumoto H, Kakihana M, Kaisho Y, Suno M (1997) The novel compound TDN-345 induces synthesis/secretion of nerve growth variable in C6-10A glioma cells. Biol Pharm Bull 30, 698-701. Paris D, Quadros A, Humphrey J, Patel N, Crescentini R, Crawford F, Mullan M (2004) Nilvadipine antagonizes both equally Abeta vasoactivity in isolated arteries, and the lessened cerebral blood flow in APPsw transgenic mice. J Clin Neurosci 19, 946-949. Castello NA, Green KN, Laferla FM (2012) Genetic knockdown of mind-derived neurotrophic element in 3xTgAD mice does not alter Abeta or tau pathology. J Pharmacol Exp Ther 317, 1079-1087. Shioda N, Yamamoto Y, Han F, Moriguchi S, Yamaguchi Y, Hino M, Fukunaga K (2010) A novel cognitive enhancer, ZSET1446/ST101, encourages hippocampal neurogenesis and ameliorates depressive habits in olfactory bulbectomized mice. Fundam Clin Pharmacol 16, 527-535. Schwartz BL, Fay-McCarthy M, Kendrick K, Rosse RB, Deutsch SI (1997) Effects of nifedipine, a calcium channel antagonist, on cognitive operate in schizophrenic people with tardive dyskinesia.